

December 13, 2019

OTC Markets Group, Inc.
304 Hudson Street, 2nd Floor
New York, New York 10013

Re: Amfil Technologies, Inc.

To Whom It May Concern:

I have been retained as corporate counsel for Amfil Technologies, Inc., a New York corporation (the “Company”), and have been asked to provide a letter to OTC Markets Group, Inc. (“OTC Markets”) with respect to the information publicly disclosed by the Company and published in the OTC Disclosure and News Service. OTC Markets is entitled to rely on this letter in determining whether the Company has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933, as amended (“Securities Act”).

I am a U.S. resident. I am licensed to practice law in the State of Georgia and the entire United States. I have not been prohibited from practicing before the U.S. Securities and Exchange Commission (“SEC”). I am not currently, nor have I ever been, suspended or barred from practicing in any state or jurisdiction, and have never been charged in a civil or criminal case in my 43 years of practice. I have been retained by the Company for the purpose of reviewing and rendering a legal opinion as to the current information supplied by the Company.

I do not beneficially or otherwise own any shares of the Company’s shares, and have no agreement to receive in the future any such shares in payment for services or otherwise.

As to questions of fact material to such opinions, I have, where relevant facts were not independently established, relied upon statements by principal officers of the Company, public officials, and other sources. I have made such further legal and actual examination and investigation as I deem necessary for purposes of rendering this opinion. In my examination, I have assumed the genuineness of all signatures, the legal capacity of natural persons, the correctness of facts stated to me by principal officers and directors of the Company, the authenticity of all documents submitted to me as originals, the conformity to original documents of all documents submitted to me as certified or photostatic copies, and the authenticity of the originals of such copies. I have also assumed that such documents have been duly authorized, properly executed, and delivered by each of the parties thereto other than the Company. I have no reason to believe that such records, certificates or documents of the Company that I have reviewed are not accurate, authentic or reliable.

I have reviewed the following documents concerning the Company (“Information”) posted at <https://www.otcmarkets.com/stock/FUNN/disclosure> in connection with the preparation of this Letter:

1. A copy of the Company’s Information and Disclosure Statement and Annual Financial Statements and Footnotes for the period ending June 30, 2019 and Quarterly Report for the period ending September 30, 2019, published on December 13, 2019.

Based on the examination and inquiry set forth above, I am of the opinion that the Information: (a) constitutes “adequate current public information” concerning the common stock of the Company quoted on the OTC Markets (“Securities”) and the Company itself, and “is available within the meaning of Rule 144(c)(2) under the Securities Act; (b) includes all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934, as amended (“Exchange Act”); (c) complies as to form with the OTC Markets’ Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcmarkets.com; and (d) has been posted through the OTC Disclosure and News Service.

The financial statements are not audited and were prepared by Ben Castanie, the Company’s Chief Financial Officer. Mr. Castanie’s many years of financial reporting experience with the Company and his knowledge of finance and accounting qualifies him to prepare the Company’s unaudited financial statements.

The Company’s transfer agent is American Stock Transfer & Trust Company. The Transfer Agent is registered with the Securities & Exchange Commission. I confirmed with the Transfer Agent and Management that the number of authorized and issued/outstanding common shares shown in the Information is listed correctly in the Information and Disclosure Statement for the periods ending above.

I have spoken on numerous occasions with Management and the Directors of the Company, Roger Mortimer and Ben Castanie, and have reviewed the Information, as amended, published by the Company through OTC Disclosure News Service, and have discussed the Information with such Management and the Directors of the Company. To my best knowledge after inquiry of Management and the Directors of the Company, neither the Company, nor its Officers and Directors, nor any holder of 5% or more of the securities of the Company, nor this counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

The opinions set forth herein are expressed as of the date hereof and remain valid so long as the documents, instruments, records and certificates I have examined and relied upon as noted above are unchanged and the assumptions I have made, as noted above, are valid. If any facts or documents are determined to be incorrect, misstated, or misrepresented, then the opinion or

opinions expressed herein may not continue to be valid. Furthermore, I disclaim any undertaking to advise you hereafter of developments hereafter occurring or coming to my attention, whether or not the same would (if now existing and known to this office) cause any change or modification herein.

Neither the Company, nor its predecessors, is or ever was a "shell company" as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934.

The opinions expressed herein are solely for the benefit of the OTC Markets Group, which is entitled to rely upon this letter. I hereby grant OTC Markets Group full and complete permission and rights to publish this letter through the OTC Disclosure and News Service for viewing by the public and regulators. This opinion may not be relied upon by any other party for any other purpose and may not be reproduced or distributed (except to governmental or regulatory agencies as required by regulation or law) without the prior written permission of named counsel.

Sincerely,

A handwritten signature in cursive script that reads "Gerald L. Baxter".

Gerald L. Baxter